GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MyMD Pharmaceuticals Inc (NAS:MYMD) » Definitions » Float Percentage Of Total Shares Outstanding

MyMD Pharmaceuticals (MyMD Pharmaceuticals) Float Percentage Of Total Shares Outstanding : 99.90% (As of Jun. 18, 2024)


View and export this data going back to 2021. Start your Free Trial

What is MyMD Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, MyMD Pharmaceuticals's float shares is 2.31 Mil. MyMD Pharmaceuticals's total shares outstanding is 2.31 Mil. MyMD Pharmaceuticals's float percentage of total shares outstanding is 99.90%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, MyMD Pharmaceuticals's Insider Ownership is 33.54%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, MyMD Pharmaceuticals's Institutional Ownership is 0.92%.


MyMD Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

MyMD Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=2.31/2.31
=99.90%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MyMD Pharmaceuticals (MyMD Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MyMD Pharmaceuticals Inc (NAS:MYMD) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
Address
855 North Wolfe Street, Suite 601, Baltimore, MD, USA, 21205
MyMD Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. It is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-1R is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and a monoamine oxidase enzyme type B.
Executives
Paul Rivard officer: EVP of Operations, GC C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Caroline C Williams 10 percent owner 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Adam Kaplin officer: Chief Scientific Officer C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Jude Uzonwanne director C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Craig Eagle director POST OFFICE BOX 4590, NEW YORK NY 10163
Chapman Christopher C Jr director, officer: President, Chief Med. Officer C/O STAR SCIENTIFIC, INC., 7475 WISCONSIN AVENUE, SUITE 850, BETHESDA MD 20814
Ian Rhodes officer: Interim CFO 1375 KINGS HIGHWAY EAST, FAIRFIELD CT 06824
Stuart M Benson officer: Chief Financial Officer EMPIRE STATE BUILDING, 350 5TH AVE., SUITE 7520, NEW YORK NY 10118
Hudson Bay Capital Management Lp 10 percent owner 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Sander Gerber 10 percent owner C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Robert C Schroeder director 37 MAIN STREET, COLD SPRING HARBOR, NEW YORK NY 11724
Howard Yeaton officer: CEO, CFO 79 LLOYD ROAD, HOHOKUS NJ 07423
Tarbox Richard C Iii director AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086
Christopher C Schreiber director AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086

MyMD Pharmaceuticals (MyMD Pharmaceuticals) Headlines

From GuruFocus